한양대학교 의과대학 산부인과학교실에서는 1979년 1월초부터 1988년 12월말까지 만 10년동안 16례의 자궁육종을 경험하여 다음과 같은 결과를 얻었다. 1. 자궁육종의 조직학적 유형별 분류는 자궁평활근육종(leiomyosarcoma) 10례(62.5%), 자궁내막기질육종(endometrial stromal sarcoma) 4례(25%), 그리고 혼합 뮬러씨종양(malignant mixed M llerrian tumor) 2례(12.5%) 등이며, 자궁육종의 양성 자궁근종에 대한 빈도는 10/1,511으로 0.62%이었다. 2. 평균연령은 38.1세이고, 평균 분만횟수는 1.6회이었다. 연령별분포는 41~50세가 6례(38%)로 가장 많았으며, 21~30세가 5례(31%), 31~40세가 2례(13%), 그 이외의 20세이하, 51~60세, 그리고 61~70세가 각각 1례(6%)이었다. 임상증상은 불규칙한 질출혈이 7례(4%)로 가장 많았으며, 하복부동통이 5례(31%), 그리고 급격한 종괴증대가 4례(25%)순이었다. 3. 암기는 제 1기가 10례(62.5%), 제 2기는 없었고, 제 3기가 1례(6%), 제 4기가 2례(12.5%)로 폐로의 전이가 있었다. 또한 암기가 증가함에 따라 평균 생존율은 감소하는 경향을 보였다. 4. 10 high power field당 세포분열수에 따른 평균 생존율은 1~4개가 38개월, 5~9개가 29.7개월, 그리고 10개이상이 16개월로 세포분열수가 증가함에 따라 평균생존율 또한 감소하는 경향을 보였다. 5. 평균 추적기간은 22.4개월(1~95개월)이었고, 수술요법후 항암 화학요법을 6회이상 투여한 후 이차추시개복술을 새행하였던 4례에서 병변이 전무한 것으로 관찰되었으며, 종양지표로 10례에서 CA-125를 추적 조사하였으나, 이 중 2례(20%)에서만 현저한 증가와 임상경과와의 상관관계가 있었으나 더 많은 례수의 추적조사가 요구된다.

Uterine sarcoma which was originated from uterine muscles and /or connective tissues, was very rare malignant tumor. There were only a few case reports in Korea. Sixteen cases of uterine sarcoma were investigated at the Department of Obstetrics and Hynecology in Han-Yang University Hospital between Jan. 1979 and Dec. 1988 for 10 years. The results were as follows: 1. During this period, the incidence of sarcomatous degeneration among 1,511 cases of benign leimyoma was 0.62 %. The distribution of uterine sarcoma by histologic type was 10 cases (62.5 %) for leiomyosarcoma, 4 cases (25 %) for endometrial stromal sarcoma and 2 cases (12.5 %) for malignant mixed M llerian tumor. 2. The average age and parity were 38.1 and 1.6. The most common symptom was irregular vaginal bleeding (44 %), lower abdominal pain (31 %) and abdominal palpable mass in order of frequency. 3. The distribution by FIGO clinical stage was 10 cases (62.5 %) for stage I, 1 case (6 %) for stage III, 2 cases (12.5 %) for stage IV and 3 cases (19 %) for recurrence. Mean survival time has been seemed to be decreased with increasing stage. 4. The mean survival time seemed to be decreased with increasing numbers of mitotic figure per 10 high power field. 5. The mean follow-up period was 22.4 months (1 ~ 95 months). Second look operation was performed for 4 cases after 6 courses of post-operative chemotherapy, and negative findings were found at all patients histopathologically. Serial CA-125 levels were measured as a tumor marker in monitoring patients, the positive rate was only 20 %. Further study was needed to make a conclusion for usefulness of CA-125 as a tumor marker.